OrbusNeich Medical to invest 300M yuan in largest R&D and production base in Hangzhou

OrbusNeich Medical (06929) plans to invest 300 million yuan in a vascular interventional medical device R&D and production base in Hangzhou, China. The facility will be the company's largest and have an annual capacity of about 2.4 million units.

“新基地将成为旗下最大的研发及生产设施。”beta.zhitongcaijing.com

• 1 source
• beta.zhitongcaijing.com港股异动 | 业聚医疗(06929)升10% 拟投资3亿元建设旗下最大研发及生产基地Mar 29, 2023

Summarized from public sources; check the original articles before acting on it.